Cytogenetic and Fluorescence in situ Hybridization Profile of Pediatric Acute Lymphoblastic Leukemia in a University Hospital in South India

Latha Sneha Magatha\textsuperscript{a} Julius Xavier Scott\textsuperscript{a} Gayathri Subramaniam\textsuperscript{b} Thirugnanasambandan Chandrasekaran\textsuperscript{a} Solomon Franklin Durairaj Paul\textsuperscript{b} Teena Koshy\textsuperscript{b}

\textsuperscript{a}Division of Pediatric Hemato-oncology, Department of Pediatrics, Sri Ramachandra Institute of Higher Education and Research, Chennai, India; \textsuperscript{b}Department of Human Genetics, Sri Ramachandra Institute of Higher Education and Research, Chennai, India

Highlights of the Study
- We report the frequency of cytogenetic abnormalities in children with acute lymphoblastic leukemia referred to a university hospital.
- In our study, 29.5% of the patients had chromosome anomalies and 46.4% had nonrandom abnormalities detected by interphase fluorescent in situ hybridization.
- Gain of RUNX1, KMT2A, and ETV6/RUNX1 fusion was observed in a significant number of patients.

Keywords
Pediatric acute lymphoblastic leukemia · Cytogenetics · BCR/ABL1 · ETV6/RUNX1 · KMT2A rearrangement · TCF3-PBX1

Abstract
Objective: The purpose of this study was to evaluate the cytogenetic and fluorescent in situ hybridization (FISH) profile in children with acute lymphoblastic leukemia (ALL), referred to a university hospital in a 5-year 6-month period. Subjects and Methods: Cytogenetic analysis of the bone marrow aspirate specimens of 91 patients was performed by standard Giemsa (G)-banding and interphase FISH (iFISH). Results: The frequency of chromosomal abnormalities detected by G-band staining was 29.5%, and the frequency of nonrandom abnormalities with independent prognostic significance identified by iFISH was 46.4%. The abnormality with the highest frequency was gain of RUNX1 ($n=18$, 21.4%), followed by ETV6/RUNX1 fusion ($n=7$, 8.3%), and gain of KMT2A ($n=6$, 7.1%). Additionally, rarely reported gains of ETV6, PBX1, and ABL1 were observed at a frequency of 6% ($n=5$), and the deletion of ETV6 and TCF3 was seen at a frequency of 3.6% ($n=3$) and 2.3% ($n=2$), respectively. A 10-year-old with intrachromosomal amplification of chromosome 21 was also observed. Conclusions: This study strengthens and widens the current knowledge of the cytogenetic landscape of pediatric ALL.

Introduction
Acute lymphoblastic leukemia (ALL) is the most frequent hematologic malignancy detected in the pediatric population and accounts for approximately 25% of can-
cancer diagnoses among children younger than 15 years of age [1, 2]. This neoplasia is characterized by the abnormal proliferation of immature lymphoid cells, and the diagnosis is based on medical examination, flow cytometric immunophenotyping, cytochemical characteristics, and genetic findings [1].

In genetic analyses, conventional Giemsa (G)-banding is commonly used to detect chromosomal abnormalities in ALL [3]. However, this method has a few limitations; sometimes poor-quality chromosomes with indistinct banding for an accurate analysis are obtained, other times chromosomes may not be available for analysis and hence must be designated as a culture failure. Additionally, identification of certain subtle rearrangements, such as translocation of ETV6/RUNX1, is not possible, and this would require the application of interphase fluorescent in situ hybridization (iFISH) for detection [4, 5]. Hence, chromosomal analysis with iFISH is more effective in diagnosing certain cryptic translocations [6]. In most countries, it has been established that genetic abnormalities can be identified in 75%–80% of childhood ALL by standard chromosomal and iFISH analyses [2, 7]. Both these approaches group patients into favorable and unfavorable prognostic subgroups; the former includes hyperdiploidy and translocation (t) 12; 21 and the latter includes hypodiploidy, amplification of chromosome 21, t (9; 22), and KMT2A rearrangements.

Global studies also suggest that the frequency of genetic abnormalities in childhood ALL vary by ethnicity and the geographic region [8]. However, there remain limited figures from India; the reported data showing a higher proportion of children with unfavorable cytogenetics [9]. Since information on the cytogenetic profile among children belonging to south India is fairly scarce, it is still unclear whether these children present aberrations typically associated with poor or favorable prognoses more frequently than other ethnicities. The aim of this study was to report the chromosome abnormalities in cytogenetically evaluated pediatric patients with ALL, treated at a single university hospital in Chennai between October 2014 and April 2020.

Materials and Methods

This study was conducted in the Division of Pediatric Hematology-Oncology, Department of Pediatrics in collaboration with the Department of Human Genetics, Sri Ramachandra Institute of Higher Education and Research (Chennai, India). All the patients younger than 18 years at the time of diagnosis and undergoing treatment for ALL were included in this study. Patients presenting with leukemia other than progenitor B-cell ALL were excluded.

For patients who had a relapse of ALL, only the findings at initial diagnosis were considered. The study was approved by the Institutional Ethics Committee (reference no: IEC-NI/14/JAN/38/03), and an informed assent was obtained from the parents.

Bone marrow aspiration was performed and processed for karyotyping by standard methods [10]. At least 10 metaphases were analyzed, and any numerical or structural chromosome abnormalities observed were reported in accordance with the ISCN 2020 [11]. FISH using commercial probes was performed as per the manufacturer’s protocol and included the LSI™ ETV6/RUNX1 dual color (DC), dual fusion (DF) translocation probe, LSI™ BCR/ ABL DC DF translocation, LSI™ TCF3/PBX1 DC DF translocation, and the LSI™ MLL DC, break apart rearrangement probes (Abbott Molecular, IL, USA). Analysis was conducted following the American College of Medical Genetics technical standards and guidelines for iFISH [12]. Two hundred interphase nuclei were scored for each probe by 2 independent analysts. If there were discrepant results, additional nuclei were examined by a third technologist. Probes were validated and cutoff values were determined in-house, before clinical use. To establish a FISH probe’s limit of detection, the upper limit of the abnormal signal pattern in normal cells was calculated. Analysis of 200 nuclei, from at least 20 individuals who had no indication of having the condition of interest, was recorded. The normal cutoff value was calculated using the statistical method of confidence interval around the mean. A cutoff of 5% for abnormal signal pattern with a confidence limit of a 95% was considered acceptable for each FISH probe used.

Standard descriptive statistics was used to analyze the data. The categorized data were expressed as both number and percentage.

Results

In this 5.5-year period, a total of 91 patients underwent cytogenetic investigation, either chromosome analysis (7.7%, n = 7) or iFISH (49.4%, n = 45) alone or in combi-
nation (42.9%, n = 39). The mean age of patients at the time of diagnosis was 6.8 ± 4.7 years, with the minimum age at diagnosis being 5 months and the maximum 17 years. Sixty-four patients (70.3%) were below the age of 10 years and 27 (29.7%) were above the age of 10 years. A majority of the patients were males (65%, n = 59). While the total leukocyte count at diagnosis ranged from 1,500/mm³ to 1,91,200/mm³, the platelet count ranged from 12,000/µL to 5,00,000/µL.

The percentage of successfully performed karyotyping improved progressively, with a success rate of 31.3% (n = 10 of 32) in 2014, 69.2% (n = 3 of 4) in 2019, and 100% (n = 5 of 5) by 2020 (Fig. 1). This is credited to the modifications in processing methods to optimize the results.

The use of FISH, introduced in our laboratory in 2014, was very useful to detect cryptic rearrangements and was used as an alternate test in cases where metaphase chromosomes were not obtained for analysis (culture failure). Using this approach, we were able to improve our reporting rate from 50% (n = 9 of 18) in 2014 to 87.5% (n = 6 of 7) in 2016 and 100% by 2020 (n = 5 of 5).

### Cytogenetic Profile

Karyotyping was performed in 46 patients at diagnosis and was successful in 44 patients (95.6%). An abnormal chromosome study was observed in 13 patients (29.5%). Low hypodiploidy, defined with the modal number 33–38 and near haploidy (modal number 24–29), was not observed in this study population. Karyotypes with structural abnormalities, either isolated or in combination with numerical abnormalities/ploidy, observed by G-banding are summarized in Table 1.

### Table 1. Abnormal karyotypes were observed by G-bANDING in our series (n = 13)

| Patient, n | Age, years | Sex | Karyotype |
|------------|------------|-----|-----------|
| 1          | 17         | M   | 92.XXY[10] |
| 5          | 11         | M   | 46.XY,del(11)(q13q23)[10] |
| 18         | 4          | F   | 45,X,-7,add(14)[10] |
| 28         | 4          | M   | 46.XY,del(9)(q12q21)[4]/46.XY[13] |
| 33         | 13         | M   | 46.XY,t(9;22)(q34;q11)[10] |
| 34         | 5 mo       | M   | 49.XY,+7,+8,+12[11]/46.XY[5] |
| 45         | 14         | F   | 46.XY,del(9)(p12)[15] |
| 50         | 4          | M   | 58~61.XXY,t(1;19)(q23;p13),del(12)(p12,+2[10],+3[5],+4[11],+5[10],+6[11],7[7],+8[7],+10[9],+11[9],+12[8],+13[5],+14[11],+15[6],+16[1],+17[11],+18[6],+21[12],+21[12],+21[2][cp12]/46.XY[8] |
| 61         | 11         | F   | 45.X,-X,t(9;12)(p24;q21),t(12;17)(p13;q12)[10]/44.X,-X,t(9;12)(p24; q21),t(12;17)(p13;q12),-22[6] |
| 64         | 4          | F   | 46.XX,add(12)(p13)[5]/46.XX[7] |
| 74         | 3          | F   | 52~55,XX[10] |
| 89         | 1          | F   | 45.XX, dic(7;9)(p11;p11), der(8)(q7;8)(p12-22;p21)[20] |
| 91         | M          |      | 42~56.XY[3]/46.XY[17] |

G, Giemsa.

### Table 2. Frequency of abnormalities detected by iFISH (n = 84)

| Loci              | Frequency, n (%) | Sex, M/F | Median age, years |
|-------------------|------------------|----------|------------------|
| **Fusions/rearrangements** |                  |          |                  |
| ETV6/RUNXI        | 7 (8.3)          | 3/4      | 4                |
| BCR/ABL1          | 4 (4.8)          | 4/0      | 9.5              |
| KMT2A             | 3 (3.5)          | 2/1      | 11               |
| TCF3/PBX1         | 3 (3.5)          | 0/3      | 2                |
| **Loss/deletion**  |                  |          |                  |
| ETV6              | 3 (3.6)          | 1/2      | 4                |
| TCF3              | 2 (2.3)          | 2/0      | 4                |
| **Gain**          |                  |          |                  |
| RUNXI             | 18 (21.4)        | 12/6     | 3.5              |
| KMT2A             | 6 (7.1)          | 6/0      | 4.5              |
| ETV6              | 5 (6.0)          | 3/2      | 3                |
| PBX1              | 5 (6.0)          | 4/1      | 4                |

iFISH, interphase fluorescent in situ hybridization.

### Cytogenetic Profile

Karyotyping was performed in 46 patients at diagnosis and was successful in 44 patients (95.6%). An abnormal chromosome study was observed in 13 patients (29.5%). Low hypodiploidy, defined with the modal number 33–38 and near haploidy (modal number 24–29), was not observed in this study population. Karyotypes with structural abnormalities, either isolated or in combination with numerical abnormalities/ploidy, observed by G-banding are summarized in Table 1.

### Interphase Fluorescent in situ Hybridization

iFISH was performed for 84 patients (92.3%), and nonrandom abnormalities were observed in 39 patients (46.4%). Table 2 describes the frequency of these abnormalities detected by iFISH. Gains and losses of the targeted loci were observed, either as isolated findings or in combination with the fusion/rearrangements. Of the
### Table 3. Distribution of cytogenetic and iFISH findings (n = 39)

| Patient ID | iFISH results | Karyotype findings |
|------------|---------------|--------------------|
| 3          | BCR/ABL DC DF | 1G1O2F (100%) Fusion NA |
| 5          | MLL DC BA     | 1G1O1F (100%) Rearrangement of KMT2A 46,XY,del(11)(q13q23)[10] |
| 7          | BCR/ABL DC DF | 1G1O2F (50%) Fusion NA |
| 8          | BCR/ABL DC DF | 1G1O2F (100%) Fusion NA |
| 31         | ETV6/RUNXI DC DF | 1G1O2F (100%) Fusion NA |
| 33         | BCR/ABL1 DC DF | 1G1O2F (40%) Fusion 46,XY,(9;22)(q34;q11)[10] |
| 35         | ETV6/RUNXI DC DF | 1G1O2F (100%) Fusion 46,XY[11] |
| 38         | ETV6/RUNXI DC DF | 1G1O2F (100%) Fusion NA |
| 46         | MLL DC BA     | 1G1O1F (100%) Rearrangement of KMT2A NA |
| 47         | BCR/ABL1 DC DF | 1G1O2F (70%) Fusion NA |
| 48         | BCR/ABL1 DC DF | 1G1O2F (70%) Fusion NA |
| TCF3/PRX1 DC DF | 1G2O (23%) Loss of TCF3 |
| 50         | TCF3/PRX1 DC DF | 1G3O (77%)/2G3O (23%) Gain of PRX1 and loss of TCF3 58~61,XXY,t(1;19)(q23;p13),del(12)(p12)+2[10],+3[5],+4[11],+5[10],+6[11],-7[7],-8[7],+9[10],+11[9],+12[8],+13[5],+14[11],+15[6],+16[1],+17[11],+18[6],+21[12],+21[12],+21[2] [cp12]/46,XY[8] |
| ETV6/RUNXI DC DF | 2G4O (80%) Gain of RUNX1 |
| 51         | BCR/ABL1 DC DF | 1G1O2F (55%) Fusion NA |
| TCF3/PRX1 DC DF | 1G2O1F (70%) Fusion |
| 54         | TCF3/PRX1 DC DF | 2G3O (15%) Gain of PRX1 NA |
| ETV6/RUNXI DC DF | 2G3O (85%) Gain of RUNX1 |
| 56         | TCF3/PRX1 DC DF | 2G3O (76%)/2G2O Gain of PRX1 NA |
| ETV6/RUNXI DC DF | 3G4O (100%) Gain of ETV6 and RUNX1 |
| 58         | ETV6/RUNXI DC DF | 2G4O (85%) Gain of RUNX1 NA |
| 59         | BCR/ABL1 DC DF | 3G2O (20%) Gain of BCR NA |
| ETV6/OUNX1 DC DF | 3G4O (35%) Gain of ETV6 and RUNX1 |
| MLL DC BA  | 3F (45%) Gain of KMT2A |
| 62         | ETV6/RUNXI DC DF | 2G4O (85%) Gain of RUNX1 NA |
| 63         | TCF3/PRX1 DC DF | 1G2O1F (100%) Fusion 46,XX[10] |
| 64         | ETV6/RUNXI DC DF | 1O2F (100%) Fusion and concomitant loss of the other ETV6 allele 46,XX,add(12)(p13)[5]/46,XX[7] |
| 65         | ETV6/RUNXI DC DF | 1G2O1F (100%) Single fusion and gain of RUNX1 46,XX[15] |
| 67         | ETV6/RUNXI DC DF | 1G2O1F (85%) Single fusion and gain of RUNX1 46,XY[25] |
| MLL DC BA  | 1G1O1F (20%) Rearrangement of KMT2A |
| 68         | ETV6/RUNXI DC DF | 2G3O (75%) Gain of RUNX1 46,XY[15] |
| 70         | ETV6/RUNXI DC DF | 2G4O (22%) Gain of RUNX1 46,XY[20] |
| MLL DC BA  | 3F (25%) Gain of KMT2A |
21 patients detected with gains of \textit{RUNX1}, \textit{KMT2A}, \textit{ETV6}, \textit{PBX1}, and \textit{TCF3} (either isolated or in combination), 10 of them had a normal karyotype with no cells showing high hyperdiploidy (HHD). While for 9 patients, a karyotype was not available and HHD could not be confirmed, for 2 patients, HHD was observed. Also, as per the guidelines of Harrison et al. [13] patient # 82 was classified as intrachromosomal amplification of chromosome 21 (iAMP21) using the established criteria of 3 or more additional \textit{RUNX1} signals (5 or more signals per cell in total) with a FISH probe targeting the \textit{RUNX1} gene.

Among the fusions, the translocation of chromosomes 12 and 21, \textit{ETV6/RUNX1} fusion, was the most frequent rearrangement found in our series. The expected iFISH signal pattern of t(12;21)(p13;q22) translocation consists of 1 orange (\textit{RUNX1}), 1 green (\textit{ETV6}), and 2 fusions (der [12] and der [21]). It was detected in 7 patients (8.3%), identified solely by iFISH. In addition to having the \textit{ETV6/RUNX1} fusion, 1 patient had an abnormality in the short arm of chromosome 12 with additional chromosome material of unknown origin present on the p arm. A high frequency (4.8%, \( n = 4 \)) of the translocation of chromosomes 9 and 22 (\textit{BCR-ABL1} fusion) was also seen; 1 patient by

| Patient ID | iFISH results | Karyotype findings |
|------------|---------------|--------------------|
| 71         | TCF3/PBX1 DC DF 1G2O1F Fusion | 46,XX[14] |
| 72         | BCR/ABL1 DC DF 2G3O (65%) Gain of ABL1 | 46,XY[12] |
| 73         | ETV6/RUNXI DC DF 2G4O (68%) Gain of RUNXI | |
| 74         | MLL DC BA 3F (64%) Gain of KMT2A | |
| 75         | ETV6/RUNXI DC DF 2G3O (45%) Gain of ABL1 | 46,XY[20] |
| 76         | ETV6/RUNXI DC DF 2G4O (68%) Gain of RUNXI | |
| 77         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 78         | MLL DC BA 3F (80%) Gain of KMT2A | |
| 79         | TCF3/PBX1 DC DF 2G3O (80%) Gain of PBX1 | |
| 80         | BCR/ABL1 DC DF 3G2O (40%) Gain of BCR | |
| 81         | ETV6/RUNXI DC DF 2G4O (35%) Gain of RUNXI | |
| 82         | MLL DC BA 3F (25%) Gain of KMT2A | |
| 83         | TCF3/PBX1 DC DF 3G2O (57%) Gain of TCF3 | |
| 84         | BCR/ABL1 DC DF 1G7O (57%) Single fusion and gain of RUNXI | 46,XY[20] |
| 85         | ETV6/RUNXI DC DF 1G7O (100%) iAMP21 | |
| 86         | BCR/ABL1 DC DF 1G4O (100%) Loss of ETV6 and gain of RUNXI | 46,XY[20] |
| 87         | ETV6/RUNXI DC DF 1G4O (100%) Loss of ETV6 and gain of RUNXI | |
| 88         | BCR/ABL1 DC DF 2G3O (65%) Gain of ABL1 | 46,XY[20] |
| 89         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 90         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 91         | ETV6/RUNXI DC DF 2G4O (22%) Gain of RUNXI | |
| 92         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 93         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 94         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |
| 95         | ETV6/RUNXI DC DF 2G4O (100%) Gain of RUNXI | |

\( \text{BA, break apart; DC, dual color; DF, dual fusion; F, fusion; G, spectrum green; iAMP21, intrachromosomal amplification of chromosome 21; O, spectrum orange; iFISH, interphase fluorescent in situ hybridization.} \)
iFISH and G-banding and in 3 patients by iFISH alone. In a nucleus containing a simple balanced t(9;22), 1 orange and 1 green signal from the normal 9 and 22 chromosomes and 2 orange/green (yellow) fusion signals, one each from the derivative 9 and 22 chromosomes, will be observed (1O1G2F). Gain of the BCR and ABL1 loci, seen as either an ES (extra green or orange) signal pattern, was observed in 3 (3.6%) and 5 (6%) patients, respectively.

Abnormalities of the 11q23 region involving the KMT2A gene were detected in 3 patients (3.3%) by iFISH alone. Interphase nuclei with one fusion signal and one separate orange and green signal (1G1R1F) represents a translocation with KMT2A involvement. One patient with this rearrangement also had a deletion in the long arm of chromosome 11, possibly the one not involved in the rearrangement.

**TCF3-PBX1** fusion or t(1;19)(q23;p13.3) by iFISH was detected in 3 patients (3.5%). Abnormal hybridization would result in 1 green, 1 orange, and 2 fusion (1G102F) signals. One patient (#50), in whom the translocation was detected in the karyotype, had an atypical iFISH signal pattern interpreted as gain of PBX1 and loss of TCF3. The distribution of the abnormal cytogenetic and iFISH findings is summarized in Table 3.

**Discussion**

Fifty-five to eighty-nine percent of pediatric patients with ALL have chromosome abnormalities detected by conventional cytogenetics and FISH; the varying percentage is dependent on the number of patients studied, the year they were reported, and the populations where they have been studied [14–19]. As established in these studies, to improve the survival of children with ALL, it is important to evaluate the cytogenetic profile. We report the cytogenetic findings in 91 children with ALL spanning a period of 5 years and 6 months referred to our university hospital located in south India.

The frequency of the **BCR/ABL1** positive cases at 4.8% (n = 4) was similar to that observed in other populations reporting 5–10% [20], highlighting the fact that analysis of this fusion transcript should be mandatory in all cases of ALL as these patients may benefit from the addition of tyrosine kinase inhibitors. The frequency of **ETV6/RUNX1** at 8.3% (n = 7) was higher than that observed in 2 studies from India reporting a frequency of 4.3%–7.3% [21, 22]. A worldwide variation in the incidence of **ETV6/RUNX1** fusion has been reported with the frequency ranging from 13 to 25% [23]. **KMT2A** gene rearrangements are associated with a poor prognosis and are generally seen in infants <1 year of age [22]. In contrast, in this study, **KMT2A** rearrangement was detected in 3 patients (3.5%) aged 2, 11, and 14 years. Previous studies in India have reported either an absence of this transcript or a low frequency ranging from 1.5% to 3.1% [22].

FISH analysis is used in many laboratories to confirm the presence of previously characterized chromosome abnormalities or to rule out suspected cryptic aberrations, thus compensating the shortcomings of karyotyping including culture failure. In cases where we failed to obtain metaphases for analysis, iFISH allowed us to screen large numbers of nondividing cells. In addition, with the inclusion of FISH we were also able to detect losses and gain of loci targeted by the FISH probes.

Similar to our findings, Harewood et al. [24] reported clusters of **RUNX1** signals visible at interphase by FISH in the largest series of 20 ALL patients. However, compared to their patient series, ours differed in 2 factors; the karyotypes in all but one were normal, and the median age of our patient series was younger, 3.5 years compared to their 9 years. Mikhail et al. [25] had a study population that appeared similar to our series in that they were all 6 years old or less and karyotypes were normal in 3 of them, even though one harbored a (12;21) translocation. These authors also demonstrated that the detection of extra **RUNX1** signals by FISH was associated with overexpression of **RUNX1** measured by real-time quantitative RT-PCR. Since we did not include RT-PCR in our investigations we cannot confirm that is applicable to our patients. Of interest was one of the patients (#82) with 7 signals for **RUNX1** which was interpreted as iAMP21 as per the guidelines of Harrison et al. [26]. iAMP21 is defined as gain of at least 3 copies of part of chromosome 21 incorporating **RUNX1** [2], (5 or more signals per cell in total) with a FISH probe targeting the **RUNX1** [26]. However, it is of interest to consider whether amplification within a single chromosome has the same effect as an acquired gain of chromosome 21, and to what extent the structure and expression of the gene are altered in these different situations and directly contributes to the etiology of ALL.

**KMT2A** rearrangement most often results from translocation or partial tandem duplication, although recent published reports suggest a different mechanism by which **KMT2A** might participate in leukemogenesis, **KMT2A** amplification [27]. Homogeneously staining regions or ring chromosomes are the most common manifestations of gain/amplification seen in a karyotype, which we did not observe in our 2 patients. Gain of **KMT2A** and/or amplifications have been reported primarily in myeloid...
malignancies, therapy-related acute myeloid leukemia, or myelodysplasia [28]. In this context, our findings in B-lineage ALLs seem noteworthy. The same could be said for the \( ABL1 \) gene, which was the next most frequent gain seen in our patient series. The presence of just one extra signal for \( ABL1 \) and \( BCR \) seen in 5 and 3 patients, respectively, was interpreted as gain of these loci. However, to the best of our knowledge, there have been limited reports of such findings in pediatric ALL. Considering that there was no visible evidence of double minutes in the available karyotype, it would be worthwhile to characterize these findings with molecular techniques like microarray.

The deletion of the normal \( ETV6 \) allele was detected in 2 patients with the \( ETV6/RUNX1 \) gene fusion and 1 patient with a normal karyotype. Raynaud et al. [29] indicated that the association between the \((12;21)\) and the deletion of the nontranslocated allele of \( ETV6 \) is among the most frequent abnormalities observed in B-lineage ALLs and provides a further proliferative advantage to leukemic cells. However, there are limited reports of gain of \( ETV6 \), \( TCF3 \) deletion, or gain of \( PBX1 \) with ALL. Thus, this could be unique findings in our population and warrants exploration in a larger patient series.

**Conclusion**

There still exists a need to address racial and ethnic gaps in the cytogenetic profile of childhood ALL, the most common pediatric cancer. In this study, though the number of patients tested was small, our findings are comparable to other studies and, more importantly, add to the limited data from India.

**References**

1. PDQ Pediatric Treatment Editorial Board. Childhood acute lymphoblastic leukemia treatment (PDQ®): health professional version. In: PDQ cancer information summaries. Bethesda (MD): National Cancer Institute (US); 2020.
2. Hunger SP, Mullighan CG. Redefining ALL. Blood. 2006;107(24):9767–87.
3. Chang HH, Lu MY, Jou ST, Lin KH, Tien HF, Lin DT. Cytogenetics in childhood acute lymphoblastic leukemia in Taiwan: a single-institutional experience. Pediatr Hematol Oncol. 2006;23(6):495–506.
4. Romana SP, Coniat ML, Berger RT. \((12;21)\): a new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer. 1994;9(3):186–91.
5. Spathas DH, Stewart J, Singer IO, Theriault A, Bovey M, Connor JM. Detection of \( t \) \((12;21)\) in childhood acute lymphoblastic leukemia by fluorescence in situ hybridization. Cancer Genetics Cytogenetics. 1999;110(1):7–13.
6. Nordgren A, Heyman M, Sahlén S, Schoumans J, Söderhäll S, Nordenskjöld M, et al. Spectral karyotyping and interphase FISH reveal abnormalities not detected by conventional G-banding: implications for treatment stratification of childhood acute lymphoblastic leukemia: detailed analysis of 70 cases. Eur J Haematol. 2002;68(1):31–41.
7. Pui CH, Carroll WL, Meinhoch S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551.
8. Lim JY, Bhatia S, Robison LL, Yang JJ. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer. 2014;120(7):955–62.
9. Advani S, Pai S, Venzon D, Adde M, Kurkure PK, Nair CN, et al. Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann Oncol. 1999;10(2):167–76.
10. Arsham MS, Barch MJ, Lawce HJ, editors. The AGT cytogenetics laboratory manual. John Wiley & Sons; 2017.
11. McGowan-Jordan J, Simons A, Schmid M, editors. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature Including New Sequence-based Cytogenomic Nomenclature. Karger; 2016.

**Acknowledgment**

The authors would like to thank the study participants and the parents for permitting us to include their data.

**Statement of Ethics**

The parents of the subjects gave their written informed consent and that the study protocol was approved by the Institute’s Committee on Human Research (reference no: IEC-NI/14/JAN/38/03).

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This work was funded by Sri Ramachandra Institute of Higher Education and Research through intramural funding (GATE).

**Author Contributions**

Latha Sneha Magatha, Julius Xavier Scott, and Thirugnanasambandan Chandrasekaran performed clinical investigations, shared clinical data, and wrote clinical parts of the manuscript. Gayathri Subramaniam, Solomon Franklin Durairaj Paul, and Teena Koshy performed the cytogenetic and iFISH investigations and compiled the data. Teena Koshy drafted the manuscript. All authors read and approved the final manuscript.

**Data Availability Statement**

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
12 Mascarello JT, Hirsch B, Kearney HM, Ker- 
tering RP, Olson SB, Quigley DI, et al. Section E9 of the American Col- 
genics technical standards and guidelines: fluorescence in situ hybridi-
zaion. Genet Med. 2011;13(7):667–75.
13 Harrison CJ, Moorman AV, Schwab C, Car-
roll AJ, Raetz EA, Devidas M, et al. An inter-
national study of intrachromosomal ampli-
fulfluorescence in situ hybridization. Genet Med. 2011;13(7):667–75.
14 Chessels JM, Swansbury GJ, Reeves B, Bailey 
CC, Richards SM. Medical Research Council 
Working Party in Childhood Leukaemia. Cyto-
genetics and prognosis in childhood lympho-
phoblastic leukaemia: results of MRC UKALL 
X. Br J Haematol. 1997;99:93–100.
15 Forestier E, Johansson B, Borgrström G, Kern-
drup G, Johansson J, Heim S, et al. Cytoge-
netic findings in a population-based series of 
787 childhood acute lymphoblastic leukemias from the Nordic countries. The NOPHO Leu-
kaemia Cytogenetic Study Group. Eur J Hae-
matol. 2000;65(1):40–51.
16 De Braekeleer E, Basinko A, Douet-Guilbert 
N, Morel F, Le Bris MJ, Berthou C, et al. Cyto-
genetics in pre-B and B-cell acute lympho-
phoblastic leukaemia: a study of 208 patients diag-
nosed between 1981 and 2008. Cancer Genet 
Cytogenet. 2010;200(1):8–15.